[Lymphomas: A therapeutic update]

Area of Science:

• Onco-hematology
• Clinical Oncology
• Pharmacology

Background:

• Traditional cytotoxic chemotherapy, like CHOP, remains a standard for lymphomas.
• The landscape of onco-hematology has been significantly reshaped by novel molecular agents.
• Advances in targeted therapies and immunotherapy have expanded treatment options.

Purpose of the Study:

• To review the historical development of new molecular agents in lymphoma treatment.
• To highlight validated therapeutic strategies for lymphomas as of 2017.
• To address the optimal use of novel therapies, including combination and sequencing.

Main Methods:

• Literature review of recent advances in onco-hematology.
• Analysis of clinical data on targeted therapies and immunotherapies.
• Synthesis of current treatment guidelines and expert opinions.

Main Results:

• Immunotherapy with anti-CD20 antibodies (rituximab, obinotuzumab, ofatumumab) is established in diffuse large B-cell lymphomas.
• Anti-CD30 antibodies show promise in T-cell and Hodgkin lymphomas.
• Anti-PD1 antibodies offer new perspectives, particularly in Hodgkin's lymphoma.
• BTK inhibitors like ibrutinib are key in managing mantle cell lymphoma and Waldenström macroglobulinemia.

Conclusions:

• The integration of novel agents necessitates careful consideration of monotherapy versus combination approaches.
• Treatment decisions involve determining the optimal timing (first-line vs. relapse) for these new molecules.
• Validated strategies incorporating these advances represent the new standards of care for lymphomas in 2017.